Thu, Dec 18, 2014, 11:39 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • pdxchopin pdxchopin Mar 1, 2006 4:22 PM Flag

    VRTX has no earnings

    VRTS has a minus earning figure and it cannot keep going up forever, especially after the insider sales are done with. Be careful if you are long.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Infergen is the only FDA approved therapy for relapsers and non-responders. It's not that great. They just testetd it that way so they could get it as the only approved..blah,blah,blah

      It's SVR rates are similar to others IFN's but require much more dosing (shots)

    • ITMN sold Infergen. They no longer own it. I would say the management must have been less impressed with Infergen or they would not have sold it. I used to own shares but dumped them when the infergen sale was announced.

    • dosing schedule in a non-starter. Before albuferon is ever approved with VX950 which is unlikely---- a monotherapy will be approved.
      If you want the re-treatment crowd (over 50% of those who already treated then Intermune has the only game in town with INFERGEN (alfacon-1)

    • You gotta know how to tease out the numbers.
      No misinformation in my post. If you look closely you'll see they are from the same article.
      The tx with albuferon BTW would be 48 weeks with ribavirin. The EVR rates are very similar to interferon alpha 2a and 2b. This drug will not be recommended for relapsers. It will be used in naive patients only. Believe me, albuferon is a loser. Came way too late to this party.

    • The CEO said the results of the phase 2 clinical studies for VX702 will be out early in the second quarter. It has also been published by the company that the results will be out early in the 2nd quarter.

    • Thanks, I was on the clinical trial for Kineret, AMGN , then got Enbril, it works but want a pill. I will keep an on on site & keep it posted here. Tom

    • The company has said they expect to have the results available by then. The timeline was somewhere around there.

    • Strong chart, might be due for a correction, but it looks good from that low it had. I did like it below 9, which was early, but now it is above its 200 day moving average, with good momentum. Just have to keep a tight leash on things in this market IMO. Albuferon would definitely need 950. I would like to see the side effect profile, to see if it is any better than Peg IFN. The reduction in dosing schedule is huge though.

    • In my opinion, the value of Albuferon is in the synergistic effect with a PI like VX-950. Regardless of the combo, if Albuferon is used, then may be HGSI may be a winner with relatively low risk. What does the current chart TA indicate?

      Since all this is a long way, I am wondering also, how much of my portfolio I want in "dead money". Meanwhile, there will be other opportunities as the markets react to all this interest rate hikes both in the US and EU.


    • Don't know where Mr. Misinformation got his data, but here is a link on Albuferon.
      "A mean reduction in HCV viral load of 3.2 log at Day 28 was observed in the combined 900 mcg and 1200 mcg dose cohorts, with 69% of patients (18/26) in these cohorts showing a >2-log reduction in HCV viral load at Day 28. Undetectable viral load was observed at Day 42 (28 days after the second injection) in 23% of patients (6/26) in the combined 900 mcg and 1200 mcg dose cohorts."
      That is an excerpt.
      FWIW, I thought the chart has been favorable since about 10 bucks, and still appears so. It had a crash of sorts a while back, but I forget what the news was back then. Don't forget, IFN isn't just used for Hep. I know people who have taken it for cancer. I am not sure it will be bigger tahn 950, it would be used with 950, but will have those other applications. I think one of the concerns from a revenue standpoint was, that 950 would cut tx time from 12 months to 3, which is much fewer Alb. to sell. That should be baked into the cake though, as 950 is well known in the marketplace.

    • View More Messages
117.74+5.89(+5.27%)Dec 18 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.